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Abstract 
 
Apoptosis is critical for embryonic development, maintenance of tissue homeostasis and 
protection against malignant transformation. The Bcl-2 family of proteins plays a key role in 
intrinsic apoptosis by controlling the integrity of the outer mitochondrial membrane, and the 
multidomain pro-apoptotic Bcl-2 family members Bax and Bak are essential components of 
this pathway. The aim of this study was to provide data on the expression of these proteins in 
normal canine tissues. Two antibodies against Bax recognising different conformations of the 
protein and one antibody against Bak were validated by immunohistochemistry and 
immunoblotting using canine recombinant proteins and keratinocytes treated with ultraviolet 
light. The antibodies were used immunohistochemically to label a wide panel of histologically 
normal tissues assembled on tissue microarrays. In addition, a subset of the tissues was 
evaluated by Western blot analysis.  
Immunohistochemical and Western blot analyses revealed that both Bax and Bak are widely 
expressed in non-neoplastic tissues from adult dogs. Immunohistochemistry showed almost 
exclusively cytoplasmic labelling and prominent labelling of epithelial cells. In lymph nodes, 
immunohistochemical labelling was diffuse for both proteins and showed enhanced intensities 
in the mantle zones for Bax and the germinal centres for Bak. Strong reactivity for the active 
conformation of Bax was detected only in enterocytes and Leydig cells and in scattered 
lymphocytes. These data indicate widespread expression of Bax and Bak in normal canine 
tissues. Knowledge of the expression of Bax and Bak in normal tissues is a prerequisite in 
assessing the role of these proteins in canine neoplastic disease. 
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Introduction 
Apoptosis is a genetically controlled cell death program critical for embryonic 
development, maintenance of tissue homeostasis and protection against malignant 
transformation (Cory et al., 2003; Elmore, 2007). Two main apoptotic pathways are known, 
the extrinsic or death-receptor pathway, which is triggered by extracellular ligands, and the 
intrinsic or mitochondrial pathway. Intrinsic apoptosis is induced by many different 
intracellular signals and is regulated by the Bcl-2 protein family, which controls the integrity 
of the outer mitochondrial membrane (OMM) through interactions between members of its 
three major subgroups. One group comprises the effector multidomain pro-apoptotic members 
BAX (BCL2-associated X protein) and Bak (BCL2-homologous antagonist/killer) that are 
gateway proteins essential to intrinsic apoptosis (Wei et al., 2001). Upon an adequate pro-
apoptotic stimulus, BAX and Bak are activated, change their conformation and BAX 
translocates from the cytoplasm to the OMM, where Bak already resides. There they form 
homooligomeric pores which allow the release into the cytosol of cytochrome c and other 
proteins that induce the demise of the cell (Letai, 2008). The members of the anti-apoptotic 
subgroups (with Bcl-2 as the prototype) can bind BAX and Bak hindering their activation. 
Proteins of the third subgroup, the BH3-only proteins inhibit the anti-apoptotic proteins and, 
under some circumstances, can directly activate BAX or Bak (Cory et al., 2003). 
Studies with knock-out animals suggest an extensive functional overlap between Bax 
and Bak but also their combined functions to be essential for normal development (Knudson et 
al., 1995; Lindsten et al., 2000).  Expression studies in humans based either on mRNA or 
protein assays, including immunohistochemistry, point to a widespread tissue distribution of 
these two proteins (Oltvai et al., 1993; Krajewski et al., 1994; Kiefer et al., 1995; Krajewski et 
al., 1996). This notion is supported by immunohistochemical data from a publicly accessible 
repository (The Human Protein Atlas1). Accordingly, BAX is most strongly expressed in the 
epithelial cells of the gastrointestinal tract and trachea, urothelium, renal tubuli, breast, and 
prostate gland, in the testis and endocrine glands (thyroid, parathyroid and adrenal glands). 
Similarly, Bak is most strongly expressed in epithelial cells of the epidermis, gastrointestinal 
tract and trachea, urothelium, as well as in the lymphatic system and adrenal gland (Oltvai et 
al., 1993; Krajewski et al., 1994; Kiefer et al., 1995; Krajewski et al., 1996; The Human Protein 
Atlas1). 
Deregulation of apoptosis is a recognised mechanism contributing to tumorigenesis 
and resistance to therapy. Three specific blocks of apoptosis have been postulated at the level                                                       1 The Human Protein Atlas, http://www.proteinatlas.org (version 11, accessed august 2011) 
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of the Bcl-2 family of proteins, including (1) overexpression of anti-apoptotic members; (2) 
functional impairment or expression loss of key BH3-only proteins, or functional impairment 
or expression loss of BAX and Bak (Letai, 2008). Thus, knowledge about the expression of 
these proteins in non-neoplastic tissues is necessary to characterize their role in 
tumorigenesis. To our knowledge, there is no immunohistochemical data available yet on the 
expression of BAX and Bak in normal canine tissues. The present tissue microarray (TMA)-
based study using thoroughly validated antibodies against total BAX, activated BAX and total 
Bak, contributes to closing this gap. Catalogues of the immunohistochemical expression of 
these proteins, partially validated through western blot analyses, are provided for future 
reference e.g. in oncological studies.  
 
Material and methods 
Recombinant proteins 
cDNAs coding for canine Bak (GenBank accession number AAY19401) and Bax 
(sequence identical to GenBank BAC56139) cloned into a pGEX4t2 vector (Invitrogen) were 
available from a concomitant study (de Brot et al., unpublished data). They were expressed as 
fusion proteins with N-terminal glutathione S-transferase (GST) in BL21 Star E. coli (Invitrogen) 
as described previously (Keller et al., 2007). For western blot analysis, lysates from liquid cultures 
of bacteria expressing GST-Bak or GST-BAX were purified using glutathione Sepharose beads as 
described previously (Wimmershoff et al., 2010). For immunohistochemistry, bacteria fixed for 24 
h in 4% neutral buffered formaldehyde were embedded in paraffin wax (Wimmershoff et al., 
2010). To create a representative array, cylinders of 0.6 mm diameter (cores) of each paraffin 
block containing bacteria were transferred to a recipient block using a manual tissue arrayer 
(Beecher Instruments).  
 
Cultured keratinocytes 
Canine normal keratinocytes (Bskin cell line) were grown in Dulbecco’s Modified 
Eagles medium, irradiated with 100 mJ UVC light using a cross linker, harvested and 
processed for western blot analysis and immunohistochemistry as described by Dettwiler et 
al. (2013). 
 
Canine tissues 
For immunohistochemical analysis, TMAs containing normal organs originating each 
from at least three different adult dogs were available (Wimmershoff et al., 2010). Two 
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additional TMAs were assembled with various organs and lymph nodes, respectively, all 
freshly sampled from seven further dogs euthanised in the context of an unrelated experiment. 
These animals were free of neoplastic disease. All tissues were fixed in 4% neutral buffered 
formaldehyde for 24 h, routinely embedded into paraffin wax, and were free of 
histopathological lesions (i.e. normal). Whole sections of skin and lymph nodes were used to 
confirm TMA findings. For western blot analysis, selected tissues of these dogs were snap 
frozen in liquid nitrogen and stored at -80 °C.  
 
Antibodies  
Commercially available antibodies against human BAX and Bak were selected based on 
homology of the immunogen with the canine sequences and/or reactivity with recombinant canine 
proteins. They included: (1) a rabbit polyclonal anti-BAX antibody clone A20 (DB005, Delta 
Biolabs; immunogen: amino acids (aa) 11-30) denominated henceforth BAX-AbA20; (2) a mouse 
monoclonal anti-BAX antibody clone 2D2 (MS-711-P0, NeoMarkers; immunogen: aa 3-16) called 
henceforth BAX-Ab2D2; and (3) a polyclonal anti-Bak antibody 06-535 (Upstate; immunogen: aa 
22-38) denominated henceforth Bak-AbNT. In addition, anti-β-actin antibody ab8227 (Abcam) 
was used to normalize western blot results. 
 
Western blots 
The procedure was performed as described by Dettwiler et al. (2013), but with slight 
modifications. Equal amounts (100 µg) of protein for each sample were measured with NanoDrop 
(Thermo Fisher Scientific) and diluted in a sodium dodecyl sulfate (SDS) loading buffer, run in 
15% SDS gels and blotted onto PVDF membranes. Primary antibodies Bak-AbNT (0.5 µg/mL) or 
BAX-AbA20 (0.5 µg/mL) or BAX-Ab2D2 (0.4 µg/mL) or ab8227 (0.3 µg/mL) were applied for 
either 1 h at room temperature or over night at 4 °C. Polyclonal and monoclonal antibodies were 
diluted in Tris-buffered saline and 0.1% Tween 20 (TBST) containing 1% skimmed milk or 1% 
BSA, respectively. Secondary antibodies, either goat anti-mouse-horseradish peroxidase (HRP) 
labelled (Geno Technologies) or goat anti-rabbit-HRP labelled (Jackson ImmunoResearch), were 
applied in a 1:7500 dilution. Negative controls included omitting the primary antibody and 
antibody preincubation were performed as described below in the antibody preincubation section.  
 
Immunohistochemistry 
Sections of 2 µm were deparaffinized, rinsed in deionised water and subjected to antigen 
retrieval consisting of heating in a steamer (Pascal S2800, Dako) in EDTA buffer, pH9.0, for 20 
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min at 98 °C (Bak-AbNT and BAX-AbA20), and for 2 min at 125 °C (BAX-Ab2D2). Primary 
antibodies diluted in Antibody Diluent (S2002, Dako) were incubated in a moist chamber 1 h at 
room temperature for BAX-Ab2D2 (2 µg/mL) and Bak-AbNT (0.5 µg/mL) or over night at 4 °C 
for BAX-AbA20 (2 µg/mL). Peroxidase-blocking solution (S2023, Dako) was applied for 10 min. 
The signal was visualized using the DAKO Detection kit (Detection system, Dako) according to 
the manufacturer’s instructions. Negative controls included omitting the primary antibody and 
antibody preincubation as described below in the next section. The immunohistochemical 
reactions were scored based on labelling intensities as follows: 0 = signal absent, 0.5 = very weak, 
1 = weak, 2 = moderate, and 3 = strong signal.  
 
Antibody preincubation  
Polyclonal antibodies Bak-AbNT and BAX-AbA20 were mixed by inversion over night at 
4 °C with purified GST-Bak or GST-BAX at a 100:1 antigen-antibody ratio, respectively, as 
described (Wimmershoff et al., 2010) and used as preincubated negative control for 
immunohistochemistry. 
 
Results 
Antibodies against human BAX and Bak, polyclonal BAX-AbA20 and Bak-AbNT 
and monoclonal BAX-Ab2D2, also recognise canine BAX and Bak expressed as Glutathione-
S-Transferase (GST) fusion proteins in bacteria. In western blots (Fig. 1A), all antibodies 
labelled bands corresponding to the full-length products (BAX: 55 kDa; Bak: 57 kDa, 
although the latter product was inconsistently present) and degradation products (as deduced 
from reactivity with an anti-GST antibody, not shown). Furthermore, immunohistochemistry 
with formalin-fixed, paraffin-embedded bacteria showed that all antibodies specifically 
reacted with formalin-resistant canine epitopes (Fig. 1B).  
Upon staining keratinocytes, BAX-AbA20 elicited a weak cytoplasmic punctate to 
diffuse signal that was enhanced after UV treatment (Fig. 1C). BAX-Ab2D2 elicited no signal 
in untreated, non-apoptotic cells and a strong, granular cytoplasmic signal in treated apoptotic 
cells (Fig. 1C). Western blot analysis with BAX-Ab2D2 revealed a specific band (21 kDa) 
that was more pronounced after irradiation (Fig. 1D). Bak-AbNT showed a cytoplasmic 
punctate immunohistochemical signal that was enhanced after UV-treatment (Fig. 1C). 
Western blot analysis revealed a specific band (24 kDa) that was enhanced in treated cells 
(Fig. 1D). Data from a detailed time course experiment documenting enhancement of the 
signals after UV-treatment is reported in Appendix A, Supplementary material.  
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Fig. 1  Validation of Bax-AbA20, BAX-Ab2D2 and Bak-AbNT antibodies using (A, B) recombinant canine 
proteins and (C, D) cultured canine keratinocytes 
A. Western blots with lysates of bacteria expressing indicated Glutathione-S-Transferase (GST) fusion protein; 
B. Immunohistochemistry with formalin-fixed, paraffin-embedded bacteria (0.6 mm cores) expressing indicated 
GST fusion protein; C. Immunohistochemistry of canine cultured keratinocytes collected at 12 h after irradiation 
(UV) and non-irradiated controls (Co). All reactions were done using indicated antibodies; all 
immunohistochemical reactions visualized with AEC chromogen, hematoxylin counterstain; D. Western blots 
with lysates of keratinocytes collected at 12 h after irradiation (UV) and non-irradiated controls (Co). 
 
 
 
 
The antibodies were specific for canine BAX and Bak and labelled these proteins at 
physiological levels, with labelling intensities appearing to be proportional to the intracellular 
protein amounts detected. More importantly, BAX-Ab2D2 appeared to label 
immunohistochemically a form of BAX present only in cells committed to apoptosis. 
Using normal canine organs in TMAs, labelling with BAX-AbA20 was observed 
almost exclusively in the cytoplasm (Table 1). The signal intensities ranged from moderate to  
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Fig. 2  Immunohistochemistry of canine tissues using BAX-AbA20 antibody 
A. Skin: epidermis diffusely labelled with weak-to-moderate intensity; B. Skin, BAX-AbA20 preabsorbed with 
GST-BAX protein: complete absence of signal; C. Small intestine: strong labelling of enterocytes; D. Small 
intestine, BAX-AbA20 preabsorbed: complete absence of signal; E. Testis: Leydig’s cells strongly labelled, 
weak-to-moderate cytoplasmic and intranuclear signal in most spermatic maturation stadia; F. Testis, BAX-
AbA20 preabsorbed: residual signal in the Leydig’s cells; G. Urethra: labelling intensity gradient from weak 
(basal) to strong (apical) throughout all urothelial layers; H. Urinary bladder, BAX-AbA20 preabsorbed: residual 
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Cont’d Fig2. granular signal in the apical urothelial cells; I. Prostata: weak-to-moderate labelling of epithelial 
cells; J.Mammary gland: weak labelling of epithelial cells; K. Trachea: gradient from moderate (basal) to strong 
(apical)throughout the epithelium; L. Thyroid: strong labelling of follicular epithelial cells; M. Liver: weak-to-
moderate labelling of hepatocytes; N. Lymph node (cortex): labelling strong in the mantle zone and 
interfollicular region and weak in the germinal center; insert: detail view of the boundary between germinal 
center, mantle zone, and interfollicular region; O. Lymph node (medulla): weakly labelled lymphocytes. All 
reactions visualized with AEC chromogen, hematoxylin counterstain. 
 
 
Table 1. Immunohistochemical expression of BAX in canine non-neoplastic tissues 
      
Signal intensity score with indicated 
antibody 
Organ system Organ Cell type BAX-AbA20 BAX-Ab2D2 
Bax-AbA20 
preabsorbed 
Integument Skin Epidermis 2 0.5 (<1%) e 0 
  Sweat/Sebaceous glands 0 0-2 0 
   Fibroblasts 0 0 0 
Digestive Esophagus Epithelial cells 2 0-0.5 0 
 Salivary glands Serous acini 1-2 0.5-1 0 
  Mucous acini 1-2 0.5-1 0 
 Stomach Parietal cells 2 
i 2 i 2 i 
  Chief cells 0 0 0 
 
Small intestine 
(duodenum, 
jejunum) 
Enterocytes 1 to 2-3 a 2-3 a 0 
  Smooth muscle (L. muscularis ) 0 0 0 
  Brunner's glandular cells  0 0 0 
 Large intestine Enterocytes 1-2 0-3 
a 0 
 Liver Hepatocytes and stellate cells 1-2 0.5-1 0 
 Pancreas endocrine and exocrine 0.5 0.5 0 
Respiratory Trachea Epithelial cells 2-3 b 0-3 b 0 
  Submucosal fibroblasts 0 0 0 
 Bronchi Epithelial cells 0.5-1 0 0 
 Alveoli Pneumocytes 0 0 0 
   Macrophages 1-2 0.5-2 0 
Urinary Kidney Glomeruli 0-0.5 0 0 
  Proximal tubules 1-3 
i 1-2 i 1-2 c,i 
  Distal tubules 2-3
 i 1-2 i 1-2 c,i 
 Bladder Epithelial cells 1-2 
b,c 0.5-1 a 1-2 (<5%) d,e 
  Smooth muscle 0-0.5 0 0 
 Urethra Epithelial cells 2-3 
b 0-1 0 
Reproductive Ovary Parenchyma 0-0.5 c 0-1 n.a. 
  Connective tissue 0 0 n.a. 
 Uterus Endometrium 0.5-2 2 n.a. 
  Myometrium 0 0 n.a. 
  Stroma 0 0 n.a. 
 Mammary gland Glandular epithelial cells 1 
e 0 0 
  Myoepithelial cells 0 0 0 
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Prostate gland Glandular epithelial cells 1-3 0 0 
  Basal cell layer 1-3 0.5-1 0 
 Testis Spermatogonia 0.5-1 
g 0 0 
  Spermatocytes 0.5-1 
g 0 0 
  Spermatids 0.5-1 
g 0 0 
  Sertoli cells 0.5-1 0-0.5 (<5%) 
e 0 
  Leydig's cells 1-3 3 1-2 (<5%) 
d,e 
 Vagina Epithelial cells 1-3 
a 0.5 n.a. 
Muscular Heart muscle Cardiomyocytes 0-0.5 0 n.a. 
 Skeletal muscle Myocytes 0 0 0 
Lymphatic Lymph node Medullar lymphocytes 0-1 3 (10-20%) e 0 
  Interfollicular lymphocytes 0-1 
f 3 (10-20%) e 0 
  Follicular germinal center 0.5-1 
f 3 (10-20%) e 0 
  Follicular mantle zone 1-3 
f 3 (10-20%) e 0 
  Macrophages 2-3 0 1-2 
  Plasma cells 2-3 0 1-2 
 Bone marrow All cell types 1 
f 3 (50%) e 0 
 Spleen Parenchyma (red/white pulp) 0-0.5 3 (10-20%) 
e 0 
  Connective tissue 0 0 0 
  Leukocytes other than lymphocytes 2-3 3 0 
 Palatine tonsil  Lymphocytes 0-3 
f 3 (10-20%) e 0 
  Epithelial cells 1-2 0 0 
  Macrophages 2 3 0 
 Thymus Lymphocytes 0-0.5 3 (10-20%) 
e 0 
Endocrine Adrenal gland All cortical zones 1 1 0 
  Medulla 0 0 0 
 Thyroid Follicular and medullary cells 2-3 0 0 
 Parathyroid Glandular cells 0.5 0 0 
Nervous 
System 
Spinal cord 
(various regions) Gray matter 1 (<5%) 
e,h 0 n.a. 
 White matter 0 0 n.a. 
 
Brain (various 
regions) Gray matter 2 (<5%) 
e,h 0 n.a. 
  White matter 0 0 n.a. 
 Cerebellum Purkinje cells 2 0 n.a. 
   Granular cells  0 0 n.a. 
a: gradient from basal stronger to apical weaker    
b: gradient from basal weaker to apical stronger    
c: additional granular pattern (score 2-3)    
d: exclusively granular pattern     
e: percentages refer to approx. portion of cells with indicated score    
f: including some (up to 20%) stronger staining cells (score 2-3)    
g: in addition nuclear signal (score 0-3)    
h: diffuse weak signal (score 0.5) of the neuropil and axons     
i: weak residual signal (score 1 in the parietal cells and 0.5 elsewhere) in the negative control without primary antibody 
n.a.= not available     
 
 13 
 
 
 
 
 
 
 
 
Fig. 3  Immunohistochemistry of canine tissues using BAX-Ab2D2 antibody 
 
A. Skin: almost complete absence of signal in the epidermis; B. Small intestine: strong labelling of villous 
enterocytes; C. Testis: strong labelling of the Leydig’s cells; D. Trachea: very weak signal in all epithelial cell 
layers; E. Prostata: almost complete absence of signal; F. Mammary gland: complete absence of signal; G. Liver: 
weakly labelled hepatocytes; H. Lymph node (cortex): strongly labelled scattered lymphocytes (approx. 10-
20%); I. Lymph node (medulla): strongly labelled scattered lymphocytes. All reactions visualized with AEC 
chromogen, hematoxylin counterstain. 
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strong (score 2-3) in intestinal, urethral, urinary bladder and tracheal epithelia, and in 
Leydig’s cells. An exception was a moderate to strong intranuclear signal in some of the 
spermatogonia and spermatocytes.  A weak to moderate cytoplasmic signal (score 1-2) was 
observed in the epidermis, in esophagal, renal tubular and prostatic epithelia, and in fewer 
than 5% of the neurons, with only a weak signal evident (score 0-1) in mammary gland 
epithelia and part of the spermatogonia and Sertoli cells (Fig. 2). Renal glomeruli and adrenal 
medulla were negative or very weakly labelled. The tracheal epithelium and the urothelium 
showed an intensity gradient increasing from basal to apical, while in the intestinal epithelium 
the gradient appeared to be inversed. In the lymph nodes BAX-AbA20 elicited a diffuse  
labelling of lymphocytes with enhanced intensity in the mantle zone. Negative controls 
showed occasional residual staining as detailed in Table 1 and Fig. 2. 
BAX-Ab2D2 showed overall less reactivity than BAX-AbA20 (Table 1) and elicited a 
moderate to strong specific cytoplasmic signal only in enterocytes and Leydig’s cells. A very 
weak signal was observed in tracheal, urinary bladder and urethral epithelia, prostatic basal 
cell layers and alveolar macrophages. In lymph nodes, BAX-Ab2D2 intensely labelled 
scattered individual cells accounting for 10-20% of lymphocytes (Fig. 3H and I). The 
remaining tissues were negative. 
Immunoreactivity with Bak-AbNT was exclusively cytoplasmic (Table 2). The signal 
intensity ranged from moderate to strong in intestinal, urethral, mammary gland and tracheal 
epithelia, from weak to moderate in the epidermis and esophagal and prostatic epithelia and 
was weak in most of the spermatogonia, Sertoli cells and cardiomyocytes (Fig. 4). Neurons, 
renal glomeruli and adrenal medulla were negative or very weak. Labelling of whole skin 
sections elicited a diffuse cytoplasmic signal in all epidermal layers with intensities varying 
between samples from weak to moderate. Basal and spinous layers sometimes showed a 
superimposed punctate pattern with further cell types in the skin labelled variably, including 
endothelia of capillaries, fibroblasts and mast cells (Fig. 4A). The signal intensity in lymph 
node tissues was moderate to strong in germinal centers, moderate in the paracortex, and 
weak in the mantle zone and medullary cords (Fig. 4M-O). Results of the negative controls 
are detailed in Table 2 and Fig. 4. 
These results indicated a widespread expression of BAX and Bak in canine adult 
normal tissues. Immunohistochemical reactivity with antibody BAX-Ab2D2, which in vitro 
reacted immunohistochemically mainly with keratinocytes committed to apoptosis was 
clearly weaker than that of the total BAX marker BAX-AbA20, with a few exceptions. 
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Table 2. Immunohistochemical expression of Bak in canine non-neoplastic tissues 
      
Signal intensity score with 
indicated antibody 
Organ system Organ Cell type Bak-AbNT Bak-AbNT preabsorbed 
Integument Skin Epidermis 1-2 0-0.5 
  Sweat/Sebaceous glands 1-2 0 
   Fibroblasts 2 0 
Digestive Esophagus Epithelial cells 1-2 0 
 Salivary glands Serous acini 1 0 
  Mucous acini 2 0 
 Stomach  Pits and necks 0.5 0 
  Parietal cells 3 e 1 e 
  Chief cells 0.5-1 0 
 
Small intestine 
(duodenum, 
jejunum) 
Enterocytes 2-3 0 
  Smooth muscle (L. muscularis ) 0.5-1 0 
  Brunner's glandular cells  0.5 0 
 Large intestine Enterocytes 2-3 0 
 Liver Hepatocytes and stellate cells 1-2 1-2 
 Pancreas endocrine and exocrine 1-2 0 
Respiratory Trachea Epithelial cells 3 0 
  Submucosal fibroblasts 0-3 0 
 Bronchi Epithelial cells 1-2 0 
 Alveoli Pneumocytes 0-1 0 
   Macrophages 1-3 2 
Urinary Kidney Glomeruli 0 0 
  Proximal tubules 2 b,e 0.5-1 b,e 
  Distal tubules 2-3 b,e 0.5-1 b,e 
 Bladder Epithelial cells 1-2 a 0 
  Smooth muscle 0.5 0 
 Urethra Epithelial cells 2-3 0 
Reproductive Ovary Parenchyma 1 n.a. 
  Connective tissue 0 (50%) -1 d n.a. 
 Uterus Endometrium 2 n.a. 
  Myometrium 0.5 n.a. 
  Stroma 0 n.a. 
 Mammary gland Glandular epithelial cells 2-3 0 
  Myoepithelial cells 0 0 
 Prostate gland Glandular epithelial cells 0.5-1 0 
  Basal cell layer 2-3 0 
 Testis Spermatogonia 0.5-1 0 
  Spermatocytes 0 0 
  Spermatids 0 0 
  Sertoli cells 0.5-1 0 
  Leydig's cells 2 
1-2 (only 
granules) 
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 Vagina Epithelial cells 1-2 a n.a. 
Muscular Heart muscle Cardiomyocytes 0.5-1 n.a. 
 Skeletal muscle Myocytes 0.5 0 
Lymphatic Lymph node Medullar lymphocytes 0.5 0 
  Interfollicular lymphocytes 1-2 0 
  Follicular germinal center 2 0 
  Follicular mantle zone 1 0 
  Macrophages 2-3 2 
  Plasma cells 0-2 0 
 Bone marrow All cell types  1-3 (50%) d 0 
 Spleen Parenchyma (red/white pulp) 0.5 0 
  Connective tissue 0.5 0 
  Leukocytes other than lymphocytes 0.5 0 
 Palatine tonsil Lymphocytes 0-1 0 
  Epithelial cells 1-2 0 
  Macrophages 3 0 
 Thymus Lymphocytes 0-1 0 
Endocrine Adrenal gland Zona glomerulosa 2-3 b 0.5-1  
  Zona fasciculata 2 b 0.5-1  
  Zona reticularis 2 b 0.5-1  
  Medulla 0-0.5 0 
 Thyroid Follicular and medullary cells 2-3 0.5 
 Parathyroid Glandular cells 1 0 
Nervous System Spinal cord (various regions) Gray matter 0 
c n.a. 
  White matter 0 c n.a. 
 
Brain (various 
regions) Gray matter 0 
c n.a. 
  White matter 0 c n.a. 
 Cerebellum Purkinje cells 0 n.a. 
   Granular cells  0 n.a. 
a: gradient from basal stronger to apical weaker  
b: additional granular pattern (score 2-3)   
c: diffuse weak signal (score 0.5) of the neuropil and axons   
d: percentages refer to approx. portion of cells with indicated score  
e:  a weak residual signal (score 1 in the parietal cells and 0.5 elsewhere) is present in the negative control 
without primary antibody  
n.a. = not available  
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Fig. 4  Immunohistochemistry of canine tissues using Bak-AbNT antibody 
A. Skin: epidermis diffusely labelled; B. Skin, replicate immunohistochemistry using BakAbNT preabsorbed 
with GST-Bak: almost complete absence of signal; C. Small intestine: strongly labelled enterocytes; D. Small 
intestine, Bak-AbNT preabsorbed with GST-Bak fusion protein: complete absence of signal; E. Cortical adrenal 
gland: moderate labelling; F. Cortical adrenal gland, Bak-AbNT preabsorbed: weak residual signal; G. Testis: 
labelling strong in the Leydig’s cells and weak in some maturation stages of spermatids and in Sertoli cells; H. 
Kidney: tubuli strongly labelled, glomerulum almost negative; I. Urethra: moderate-to-strong labelling of all 
layers of the urothelium; J. Prostata: weak-to-moderate labelling of the glandular cells; K. Mammary gland: 
moderate-to-strong labelling of the glandular cells; L. Tracheal epithelium: strong labelling; M. Lymph node 
(cortex): moderate-to-strong labelling of the germinal center lymphocytes; N. Lymph node (cortex): detail view 
of the boundary between germinal center and mantle zone showing differences in signal intensity between the 
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Cont’d Fig4. two regions; O. Lymph node (medulla): weak labelling of the lymphocytes. All reactions 
visualized with AEC chromogen, hematoxylin counterstain. 
 
 
Lysates of selected organs were analysed by immunoblotting to further support the 
immunohistochemical findings. Western blot analysis of skin lysates showed specific bands 
supporting the notion that these tissues express both BAX and Bak (Fig. 5A). Identity of the 
24 kDa band was confirmed with an additional anti-Bak antibody not otherwise used due to 
low affinity (not shown). In contrast to keratinocytes, in whole skin lysates Bak-AbNT 
additionally cross-reacted with 50 and 70 kDa products (Fig. 5A, 3rd panel, lane 2), indicating 
that there may be cross-reactions outside of the epidermal compartment.  
Analysis of lysates of further tissues showed a very good agreement between both 
anti-BAX antibodies (Fig. 5B) and suggested a limited propensity to react unspecifically for 
BAX-AbA20 varying between organs and minimal for instance in palatine tonsil and lymph 
node lysates. The relative signal intensities of BAX-AbA20 matched well between 
immunoblotting and immunohistochemistry. Analysis of the same tissues with Bak-AbNT 
showed overall presence of a specific band (Fig. 5B). A further 70 kDa band was especially 
marked in extracts of liver, tonsil, lymph node and musculature and weak in spleen, kidney 
and testis. In summary, western blot analyses supported the notion that BAX and Bak are 
widely expressed in canine non-neoplastic tissues and confirmed the immunohistological 
findings for BAX.  
 
Discussion 
In this study, an immunohistochemical expression analysis of pro-apoptotic BAX and 
Bak was conducted in normal canine tissues with the aim of providing comprehensive 
catalogues of the expression of these proteins. The present data indicate that both BAX and 
Bak, similar to previous reports on human tissues (Oltvai et al., 1993; Krajewski et al., 1994; 
Kiefer et al., 1995; Krajewski et al., 1996), are expressed at high levels in epithelial cells or 
tissues containing epithelia in the dog and suggest that both proteins have a role in these 
organs under physiological conditions. In some epithelia, as for instance enterocytes (BAX) 
and the urothelium (Bak), a gradient of reactivity paralleling cell differentiation was observed. 
A possible role of these proteins in the differentiation and/or turnover of these tissues has 
been suggested (Krajewski et al., 1996; Penault-Llorca et al., 1998; Gao and Wang, 2009). In 
contrast to some studies with human tissues (Tomková et al., 1998; Batinac et al., 2007), but 
in agreement with others (Krajewski et al., 1994; Penault-Llorca et al., 1998), no gradient was 
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observed for BAX in the canine epidermis. Similarly, no gradient was observed for Bak in the 
canine colon, skin, trachea, and prostate gland, in contrast to descriptions of some human 
studies (Krajewski et al., 1996; Tomková et al., 1998; Batinac et al., 2007; Duckworth and  
 
 
Fig. 5  Western blot analysis of BAX and Bak expression in canine tissues and cultured keratinocytes 
A. Western blots of canine cultured keratinocytes (lane 1) and canine skin (lane 2) with indicated antibodies; all 
antibodies label a band of expected size (BAX: 21 kDa; Bak: 24 kDa) in all panels; in skin lysate (3rd panel, lane 
2) Bak-AbNT additionally labels bands at 50 and 70 kDa; B. Western blot of canine tissues: lane 1: liver; lane 2: 
kidney; lane 3: spleen; lane 4: tonsil; lane 5: lymph node; lane 6: testis; lane 7: skeletal musculature; lane 8: 
pancreas. Both anti-BAX antibodies label a specific marked band at 21 kDa (lanes 1, 2, 4, 5, 6, 7) and weak 
bands at 26 kDa (lanes 4, 5) and 23 kDa (lane 6) interpreted as BAX isoforms; polyclonal BAX-AbA20 weakly 
labels additional bands at 28, 40 and 70 kDa in some organs. Labelling with Bak-AbNT antibody variably shows 
two major bands at 24 kDa (corresponding to the expected size of Bak) and 70 kDa. An occasional faint 
additional band around 50 kDa (1st and 3rd panel) was attributed, at least partially, to the secondary antibody 
(not shown). All reactions were done using indicated antibodies. 
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Pritchard, 2009). The ability to demonstrate such gradients may depend upon technical factors 
such as the antibody concentration. Other possible causes of inter-study differences include 
differences in antibodies, antigen retrieval and visualization methods.  
It is noteworthy in this context that BAX-AbA20 labelling in canine lymph nodes was 
stronger in the mantle zone than in the germinal centers, as confirmed using whole sections. 
This contrasts with human and murine reports indicating either a stronger expression in the 
germinal centers compared to the remaining regions (Krajewski et al., 1994; Penault-Llorca et 
al., 1998; Agarwal and Naresh, 2002) or no differences between the lymph node 
compartments (The Human Protein Atlas1). The expression of Bak in canine lymph nodes was 
stronger in germinal centers than in interfollicular regions, similar to some studies with 
human tissues (Agarwal and Naresh, 2002) but unlike others indicating either predominance 
of labelling in the mantle zone (Krajewski et al., 1996) or no differences (The Human Protein 
Atlas1). This underlines the importance of species specific studies to establish normal 
distributions as a basis for interpreting pathological changes in disease.  
Knowledge of the expression of apoptotic-related proteins in normal tissues is a 
prerogative to study their role in disease. Defects in the regulation of apoptosis have been 
described in various diseases including autoimmune and degenerative disorders, as well as 
cancer (Elmore, 2007). The expression data for the multidomain pro-apoptotic proteins BAX 
and Bak, which are essential for intrinsic apoptosis, and the reagents for their detection in 
canine tissues presented here provide useful tools for future studies of such diseases. For 
instance, the alteration of the expression of several apoptosis-related proteins including BAX 
and/or Bak has been implicated in the genesis, progression and resistance to therapy of 
several cancer types under experimental conditions and in spontaneous disease (Cory et al., 
2003; Deng et al., 2007; Olejniczak et al., 2008; Duckworth and Pritchard, 2009). Thus, 
assessment of the expression of these proteins might be important to characterize the 
pathogenesis of these diseases and, in future, to inform therapeutic interventions.  
Since the use of antibodies raised against heterologous antigens, which is a recurrent 
situation in studies including companion animals, can be problematic (Keller et al., 2007; 
Dettwiler et al., 2013) and BAX-Ab2D2 does not cross-react with murine BAX (Hsu and 
Youle, 1997), all antibodies used here were thoroughly validated. They were formally 
demonstrated to react with the recombinant canine homologues and to label endogenous 
levels of protein in a semi-quantitative manner in UV-irradiated keratinocytes. Moreover, 
substantial differences in the immunohistochemical reactivities between the two anti-BAX 
antibodies were apparent. BAX-AbA20 and BAX-Ab2D2 bind different N-terminal epitopes 
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of BAX (within amino acid (aa) 11-30 (first alpha-helix) and aa 3-16, respectively). BAX-
AbA20 immunohistochemically labelled both non-irradiated and irradiated cells, while BAX-
Ab2D2 only labelled irradiated keratinocytes undergoing apoptosis, as described in non-
neoplastic human skin exposed to UV-light (Zuliani et al., 2008).  
This study suggested that BAX-Ab2D2 recognizes an epitope accessible 
immunohistochemically only in the active BAX conformation. Western blot data and the 
widespread punctate immunohistochemical labelling pattern observed with BAX-Ab2D2 in 
canine tissues support this notion. However, the real basis of this reactivity is not clear, since 
in biochemical studies antibodies against the very N-terminal end, such as clone 2D2, bound 
BAX independently of its conformation (Hsu and Youle, 1997). Intriguingly, Lalier et al. 
(2011) reported that antibodies targeting a region roughly corresponding to the immunogen of 
BAX-AbA20 only reacted with active BAX, while in another study both types of antibodies 
labelled BAX only after staurosporine treatment (Makin et al., 2001). The present findings 
and those of a previous immunohistochemical study indicate, however, that antibodies such as 
BAX-AbA20 label total BAX in tissues (Zuliani et al., 2007).  
To the best of our knowledge this is the first immunohistochemical analysis of a wide 
range of tissues using antibodies directed against different conformations of BAX. 
Interestingly, most organs were negative or very weakly positive for BAX-Ab2D2, although 
in some cell types (i.e. enterocytes, Leydig’s cells), a marked reactivity was observed. This 
might indicate the presence of activated BAX in these tissues. 
We document here the widespread expression of BAX and Bak in normal canine 
tissues based on immunohistochemical analysis and supported by western blot data of the 
corresponding tissue extracts. Whereas immunoblot analysis indicated high levels of 
specificity for BAX-Ab2D2 and BAX-AbA20, there were varying levels of specificity 
between tissues for Bak-AbNT. Concomitant analysis of skin and keratinocytes indicated 
presence of a cross-reacting protein outside of the epidermal compartment but pointed to a 
specific labelling of the epidermis. Thus, although western blot analysis showed Bak protein 
to be present in all tissues analysed, further investigations are required to unequivocally 
identify the cell types expressing Bak. Such studies could include either the separate analysis 
of isolated tissue components or the use of antibodies against different epitopes of Bak or 
complementary methods such as in situ hybridisation. We identified an additional antibody 
cross-reacting with canine Bak that could not be used due to low affinity (not shown).  
Besides its value for antibody validation and for confirming immunhistochemical 
findings, western blot analysis might also be useful to explain intriguing findings. One of 
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these was the presence, in maturation stages of spermatids only, of an intranuclear 
immunohistochemical signal detected using BAX-AbA20. This was the only instance of 
intranuclear BAX labelling in this study and this finding is in agreement with a previous 
investigation of human testes (Oldereid et al., 2001). The presence of two distinct bands 
specific for BAX (at 21 and 23 kDa) in the western blot of canine testicular extracts point to 
the occurrence of different isoforms of the protein which might have different subcellular 
localizations in this tissue. 
 
Conclusions 
Widespread expression of the pro-apoptotic proteins BAX and Bak was found in 
canine normal tissues. The immunohistochemical signals were almost exclusively 
cytoplasmic and were particularly prominent in epithelial cells. In addition, enterocytes and 
Leydig’s cells, as well as scattered lymphocytes were markedly labelled by an antibody likely 
recognizing the active conformational form of BAX in tissues. The detailed catalogues of the 
expression of these proteins in canine tissues provided here are usable references for studies 
investigating apoptosis-related diseases. 
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Appendix A: Supplemental material 
 
Immunohistochemical and western blot analysis of keratinocytes collected in a time 
course after treatment with UV light 
 
Antibodies BAX-AbA20, BAX-Ab2D2 and Bak-AbNT were used to label keratinocytes 
either untreated or treated with UV (100 mJ) and harvested at 30 min, 4 h, 8 h, 12 h and 24 h 
after treatment (Fig. S1). The majority of the cells underwent apoptosis and presented 
extensive immunohistochemical reactivity for cleaved caspase-3 (not shown) within 24 h of 
treatment. BAX-AbA20 elicited a faint immunohistochemical cytoplasmic punctate to diffuse 
signal in over 50% of the untreated cells (Fig. S1, first row), while BAX-Ab2D2 elicited no 
signal in untreated, non-apoptotic cells (Fig. S1, second row). Bak-AbNT showed a 
cytoplasmic punctate signal in untreated cells (Fig. S1, third row). Intensity of the 
immunohistochemical signal elicited by BAX-AbA20 appeared to be enhanced after 
treatment. This enhancement affected a large portion of cells showing morphological signs of 
apoptotic cell death. Of note, cells in an advanced state of dismantlement, i.e. with marked 
fragmentation of the nucleus, often were negative (Fig. S1, first row). Cells showing 
squamous differentiation presented in the controls and early after UV irradiation a faint 
diffuse cytoplasmic labelling with sometimes a moderate punctate pattern; at 12 h and, more 
pronounced, at 24 h after irradiation, a large number of these cells showed a much stronger 
multifocal cytoplasmic granular staining despite absence of morphological signs of cell death. 
Using BAX-Ab2D2, a strong, granular cytoplasmic signal became visible in treated cells 
showing morphological signs of apoptosis. The intensity of this signal did not noticeably 
increase with time, while the number of positive cells increased markedly from a few cells at 
30 min to large numbers of cells at 12 h and 24 h. Cells in an advanced state of dismantlement 
showed only a very faint signal. Most of the cells showing squamous differentiation failed to 
display a signal. Western blot analysis of cell lysates with antibody BAX-Ab2D2 revealed an 
increase of the amount of BAX after irradiation (Fig. S1B) in the 2 to 4-fold range after 
normalizing with β-actin (Fig. S1C). The BAX/β-actin ratio was calculated after scanning and 
measuring the intensity of each band using the ImageJ program 
(http://rsb.info.nih.gov/ij/index.html). 
Using Bak-AbNT, the intensity of the immunohistochemical signal was enhanced after 
treatment and especially in cells showing morphological signs of apoptotic cell death (Fig. 
S1A). In contrast, cells in an advanced state of dismantlement were negative. Cells showing 
squamous differentiation and not undergoing apoptosis showed a faint labelling independent 
of treatment. In a western blot, after normalizing with β-actin, the relative amount of Bak 
labelled by Bak-AbNT appeared to be approximatively increased by 2-fold in treated cells 
compared to untreated cells (Fig. S1B and C). 
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Fig. S1  Validation of BAX-AbA20, BAX-Ab2D2 and Bak-AbNT antibodies using UV-irradiated canine 
keratinocytes 
A. Immunohistochemistry with indicated antibody of keratinocytes collected at indicated time points after 
irradiation; Co 30min indicate non-irradiated controls collected at 30 min after irradiation; reactions were done 
using the indicated antibodies; B. Western blot of lysates of keratinocytes collected at indicated time points after 
UV irradiation reacted with BAX-Ab2D2 , Bak-AbNT and for beta-actin; Co indicate non-irradiated controls 
collected at indicated time points; C. Ratios of the density of the bands for BAX respectively Bak and beta-actin 
shown in B (same numbering); values of controls are indicated in red. 
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